title: Inhibitors of phosphoinositol 3 kinase and NFκB for the treatment of chronic obstructive pulmonary disease.
abstract: Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. In the present article, we review the new patents on phosphoinositide 3 kinase and NFκb inhibitors for future therapies.
authors.affiliation: Insituto de Inmunología, Facultad de Medicina, Universidad Central de Venezuela, Apartado 50109, Caracas 1050-A, Venezuela.
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Larocca
authors.forename: Dolores
authors.initials: D
authors.lastname: Moreno
authors.forename: Jenny V
authors.initials: JV
authors.lastname: Garmendia
authors.forename: Juan B
authors.initials: JB
authors.lastname: De Sanctis
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D048288:Imidazolines / Q000494:pharmacology / Q000627:therapeutic use*; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D010330:Patents as Topic; D000081082:Phosphoinositide-3 Kinase Inhibitors; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D013256:Steroids / Q000494:pharmacology / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D048288:Imidazolines; D016328:NF-kappa B; D000081082:Phosphoinositide-3 Kinase Inhibitors; D013256:Steroids; D058570:TOR Serine-Threonine Kinases